Kyrgyzstan Sterilization and Biological Effect Evaluation: Decision No. 38, Inspections and Shelf-Life Constraints

1. Key takeaways

Sterility and biocompatibility in Kyrgyzstan involve two parallel lines. On the technical line, studies for the evaluation of biological effects follow Decision No. 38 of the Council of the Eurasian Economic Commission, dated May 16, 2016 (paragraph 3 of Article 2 of Cabinet of Ministers Resolution No. 513). On the procedural line, a sterile product pushes a Class 2a device into the scope of manufacturing inspections, with an inspection period of no more than 90 calendar days (draft status). Whether a product is sterile is therefore a judgment in Kyrgyzstan that simultaneously affects the evidence requirements and the project timeline. Treating sterility as a mere technical attribute understates its regulatory weight: it moves classification, documentation, inspection exposure and even import feasibility, and it should be flagged as a controlling parameter in every registration plan.

2. Legal basis

1. Resolution No. 513 of the Cabinet of Ministers, dated August 27, 2024, paragraph 3 of Article 2: studies (trials) conducted for the evaluation of biological effects follow Decision No. 38 of the Council of the Eurasian Economic Commission dated May 16, 2016.
2. Explanatory note to the 2026 draft amendments of the Ministry of Health of the Kyrgyz Republic: manufacturing inspections apply to devices of potential risk class 2a (sterile), 2b and 3; the inspection period is no more than 90 calendar days and is not counted within the overall registration timeline (draft status, not yet in force).
3. Resolution No. 450 of the Cabinet of Ministers, dated June 29, 2026: procedures for inspections in the field of circulation of medical devices.
4. Resolution No. 513, paragraph 2 of Article 2: general safety and effectiveness requirements follow Decision No. 27 (with item 63 excluded).
5. Scope of documents waivable under the simplified pathway: includes documents concerning contained medicinal substances, sterilization and software (applicable to devices holding approvals from the eight reference jurisdictions).

3. Expert insights

Insight 1: The title of Decision No. 38 defines its scope of application.

The full title of Decision No. 38 concerns the rules for conducting studies (trials) to evaluate the biological effects of medical devices. The key phrase is biological effects: it covers the evaluation of the biological response arising from contact between the device and the human body, including dimensions such as cytotoxicity, sensitization, irritation and systemic toxicity. This document is the direct basis for biocompatibility evidence, and companies should organize their evidence around it rather than simply importing the clause numbering of the ISO 10993 series. ISO standards remain useful references, but the index that the reviewer follows is the one in Decision No. 38.

Insight 2: Separate the documentation of sterilization validation from the fact of sterility.

The simplified pathway waives documents concerning contained medicinal substances, sterilization and software. What is waived is the obligation to submit documents, not the sterile status itself. If the product is supplied sterile, that attribute still determines: first, whether a Class 2a product triggers a manufacturing inspection; second, whether outsourced sterilization sites must be fully disclosed; and third, whether the labeling and instructions for use must state the sterilization method and shelf life. A waiver of documents is not a waiver of the downstream obligations that the attribute carries.

Insight 3: Outsourced sterilization sites are a high-frequency risk point during inspections.

Article 16 of this series notes that the statutory definition of production site covers territorially separated complexes where the entire production process or specific stages of it are completed, and an outsourced sterilization facility clearly falls within it. We recommend full disclosure of outsourced sterilization sites in the registration dossier, supported by a quality agreement and sterilization validation reports. Discovering an undisclosed site during an inspection typically results in a supplemental inspection or suspension, a cost far exceeding that of early disclosure.

Insight 4: Sterile shelf life interacts directly with the import stage.

Article 31 of Law No. 216 lists among the prohibited import situations devices with less than one third of their total shelf life remaining (excluding devices without a shelf life). For sterile products, this provision binds the manufacturing date, the sterilization date and the transport cycle together: a product with a short shelf life may fail import requirements after long-distance transport. Companies should model this constraint during supply chain planning (see article 38 of this series), not discover it at the border.

Insight 5: Biological effect evidence is transferable after 2028.

Decision No. 38 is a Union-level document shared by the national and Union tracks. Biological effect evaluation evidence prepared on the national track can be reused when migrating to the Union track after 2028. Companies should therefore build the evidence in a rule-oriented format from the outset, citing the decision number and the items relied upon, so that migration becomes repackaging rather than re-testing.

4. Practical recommendations

First, add a dedicated column for sterile status in the classification rationale table. This column simultaneously determines the evidence requirements (sterilization validation), the procedural requirements (whether Class 2a triggers an inspection) and the labeling requirements (sterilization method and shelf life).

Second, disclose all sterilization-related sites completely. Include in-house sterilization facilities and outsourced sterilization plants alike, and provide quality agreements, sterilization validation reports and the records of the most recent audit of each site.

Third, structure biological effect evidence around the items of Decision No. 38. Note the referenced international standard numbers alongside, but use the items of Decision No. 38 as the primary index so the file tracks the binding text.

Fourth, plan the sterile product supply chain backwards from shelf life. Using the constraint of no less than one third of total shelf life remaining, work backwards from the manufacturing date, sterilization date and shipping date, and reflect the calculation in the logistics plan.

Fifth, add the sterilization validation report to the inspection-ready package. It should be retrievable at any time in both the registration-stage and distribution-stage inspection scenarios (see article 16 of this series).

5. Verification checklist

• □ The classification rationale table contains a dedicated sterile-status column, used to assess the inspection obligation of Class 2a products;
• □ Current text of Decision No. 38 of the Council of the Eurasian Economic Commission (May 16, 2016) obtained;
• □ Biological effect evidence structured around the items of Decision No. 38, with referenced international standard numbers noted;
• □ All sterilization-related sites fully disclosed (in-house facilities and outsourced plants), with quality agreements and sterilization validation reports;
• □ The sterile product supply chain planned backwards from the one-third remaining shelf life constraint;
• □ The sterilization validation report included in the inspection-ready package and kept current.

Regulatory information verified as of October 29, 2026.

Our services cover: pre-market pathway selection and feasibility assessment, registration dossier preparation and submission, authorized representative arrangements, local testing and clinical trial organization, manufacturing site inspection coordination, quality management system compliance support, post-market surveillance and device vigilance system setup, import and distribution compliance, and fee calculation and project budget management.

The GRZAN regulatory team consists of professionals with many years of hands-on experience in Eurasian Economic Union registration. We maintain a stable local cooperation network in Bishkek, Almaty, Tashkent and Moscow, work in Chinese, Russian and English, and provide executable solutions for foreign manufacturers on the issues most commonly encountered in CIS markets: authorized representative arrangements, notarization and legalization chains for powers of attorney, technical documentation localization, and inspection readiness. GRZAN supports manufacturers, importers and authorized representatives throughout the Kyrgyzstan registration lifecycle.

We adhere to one principle: every regulatory conclusion we publish must rest on verifiable official sources. Any figure or timeframe that cannot be verified is labeled as a practical estimate and is never presented as a legal requirement.

For project consultation on market access in Kyrgyzstan or the Eurasian Economic Union, please contact us at info@grzanglobal.com.

GRZAN | Global Medical Device Regulatory Registration and Compliance Services